Filing Flows › Madrigal Pharmaceuticals (MDGL) › R&D spending
Madrigal Pharmaceuticals (MDGL) R&D spending by quarter
Madrigal Pharmaceuticals' R&D spending was $71.8M in Q3 2026 (third quarter 2026), -21% from Q2 2026. Over the last 7 quarters it ranged from $44.2M (Q1 2025) to $174M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $71.8M | -21% | -59% |
| Q2 2026 | $91.2M | -16% | +69% |
| Q1 2026 | $109M | -7% | +146% |
| Q4 2025 | $116M | -33% | — |
| Q3 2025 | $174M | +222% | — |
| Q2 2025 | $54.1M | +22% | — |
| Q1 2025 | $44.2M | — | — |
Q3 2026 at a glance
Madrigal Pharmaceuticals, Q3 2026: revenue $431M (+50% year over year), operating margin 13.0%, net earnings $55.4M, operating cash flow $121M. The chart follows the revenue to costs, profit and cash.
Questions
What is Madrigal Pharmaceuticals' R&D spending?
Madrigal Pharmaceuticals' R&D spending was $71.8M in Q3 2026 (third quarter 2026), -21% from Q2 2026.
How has Madrigal Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $44.2M (Q1 2025) to $174M (Q3 2025).
Q3 2026 results → · How Madrigal Pharmaceuticals makes money →